A Phase 1/2 interventional study of Mirvetuximab soravtansine and Bevacizumab in Epithelial Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer, sponsored by ImmunoGen, Inc.. Completed at 12 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-14.
Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 29 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.
Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 41st largest by enrollment of the 381 interventional ones that give a count, is one of 12 that started in 2016, is one of 51 in phase 1/2, and was the 397th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →29 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
AstraZeneca · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+ · Women only
AstraZeneca · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+ · Women only
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+ · Women only
Blue Earth Diagnostics · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 204 · Phase 2 230 · Phase 3 39 · Phase 4 1
First in 1991; this study’s year is marked. 12 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 264 is above the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 35 across the 381 interventional studies, 57 across the 34 observational. Of the 418 that completed or were terminated, 122 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 500 have an industry lead sponsor. The 10 most frequent:
This study is registered under ImmunoGen, Inc., one of the names counted as AbbVie. Under that name alone:
ImmunoGen, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
AbbVie has 6 studies filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
14 of the studies in Carcinoma, Ovarian Epithelial with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT06386887Case Comprehensive Cancer CenterFasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer | 2026-11 |
| NCT06395519858 Therapeutics, Inc.A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | 2026-12 |
| NCT05335993CanariaBio Inc.A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | 2026-12-30 |
| NCT05763199University of California, DavisStandardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study comprises a Dose Escalation phase followed by a Dose Expansion phase. Dose Escalation part of the study will assess the safety and tolerability and determine the maximum tolerated dose (MTD) as the recommended Phase 2 (RP2D) dose for each regimen. Participants will be assigned to one of the 4 regimens in Dose Escalation phase: Regimen A: mirvetuximab soravtansine administered with bevacizumab; Regimen B: mirvetuximab soravtansine administered with carboplatin; Regimen C: mirvetuximab soravtansine administered with pegylated liposomal doxorubicin; or Regimen D: mirvetuximab soravtansine administered with pembrolizumab. Dose Expansion of the study will further assess safety, tolerability and preliminary anti-tumor activity of mirvetuximab soravtansine. A Dose Expansion phase is planned for Regimen A and Regimen D and will open pending Sponsor decision; participants enrolled in the Dose Expansion phase will receive study treatment at the MTD or RP2D determined during Dose Escalation. For Regimen A, participants in the Dose Expansion phase may be enrolled according to prior exposure to bevacizumab into 3 Dose Expansion Cohorts as follows: 1) Dose Expansion Cohort 1: bevacizumab naïve; 2) Dose Expansion Cohort 2: bevacizumab pretreated; and 3) Dose Expansion Cohort 3: one to three prior treatments, one of which could have been bevacizumab. A triplet Regimen (Regimen E: mirvetuximab soravtansine + bevacizumab + carboplatin) will be opened to evaluate the safety and tolerability and to assess any early signs of activity in participants dosed with the combination regimen. All mirvetuximab soravtansine doses were calculated according to adjusted ideal body weight.
Participants will continue to receive mirvetuximab soravtansine and/or the combination agent until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, whichever comes first, or until the Sponsor terminates the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
Drug: Mirvetuximab soravtansine · Drug: Bevacizumab
Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.
Drug: Mirvetuximab soravtansine · Drug: Carboplatin
Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.
Drug: Mirvetuximab soravtansine · Drug: Pegylated Liposomal Doxorubicin
Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
Drug: Mirvetuximab soravtansine · Drug: Pembrolizumab
Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.
Drug: Mirvetuximab soravtansine · Drug: Bevacizumab · Drug: Carboplatin
Also known as: IMGN853
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Adverse events (AEs) were any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function that developed or worsened during the clinical study, not necessarily having a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes previously listed. TEAEs were any AE that emerged on or after the first dose, and within 30 days of the last dose. Serious and other non-serious AEs regardless of causality are reported in the AE module.
Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 238.3 weeks)
Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
ORR was defined as percentage of participants with confirmed response (complete response \[CR\] + partial response \[PR\]). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD. The 95% confidence interval (CI) was based on binomial distribution.
Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Dose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response, as Assessed by RECIST Version 1.1
ORR was defined as percentage of participants with confirmed response (CR + PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the SLD of target lesions, taking as reference the baseline SLD.
Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Progression-Free Survival (PFS); Time From the Date Of First Dose Until The Date Of Progressive Disease (PD) Or Death By Any Cause, As Defined By RECIST Version 1.1
PFS was defined as the time from the date of the first dose of study drug until the date of PD or death from any cause, whichever occurred first, estimated using the Kaplan-Meier method. PFS was defined based on radiological assessments and determined by the investigator. PD was defined as at least a 20% increase in the SLD of target lesions, taking as reference the smallest (nadir) SLD since and including baseline. In addition to the relative increase of 20%, the SLD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: From first dose of study drug until the date of PD or death by any cause (maximum exposure: 238.3 weeks)
Duration of Response (DOR) Per RECIST v1.1 by Investigator Assessment
DOR was defined as the time from the date of the first response (CR or PR), to the date of PD or death from any cause, whichever occurred first. DOR was only defined for patients who had a best overall response of CR or PR, estimated using the Kaplan-Meier method. The response-evaluable population included all patients with radiographic assessment at baseline, who received at least 1 dose of combination treatment and had at least 1 post-dose radiographic tumor assessment or who died within 105 days of first dose.
Time frame: From the date of first objective response to the time of PD (maximum exposure: 238.3 weeks)
Gynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA)-125 Clinical Response Rate by Investigator Assessment
A CA-125 response was defined as a ≥ 50% reduction in CA-125 levels from baseline. GCIG CA125 response rate was defined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100. The CA-125 evaluable population included all participants whose pretreatment sample was ≥2.0 times the upper limit of normal, within 2 weeks prior to the first dose of combination treatment, and who had at least 1 post-baseline CA-125 evaluation.
Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Pharmacokinetics (PK) Parameter: Maximum Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total Antibody
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in micrograms/milliliter (µg/mL).
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: Cmax of N2'-[4-[(3-carboxypropyl)Dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-Deacetylmaytansine (DM4) and S-methyl DM4 (SmDM4)
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in nanograms (ng)/mL.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: Area Under the Time-Concentration Curve From Time 0 To Infinite Time (AUCinf) of Mirvetuximab Soravtansine and Total Antibody
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in mg\*hours (h)/mL.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: AUCinf of Intact DM4 and SmDM4
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Note that '9999' is used because AUCinf cannot be calculated for n\<3.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: Terminal Half-Life (t½) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were calculated using standard non-compartmental methods. The terminal t½ is an estimate (extrapolation) of the time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half (50%). If extrapolated AUC was greater than 20% (due to insufficient number of participants with data samples) the upper range of t½ was not reported.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (up to 336 hours) (additionally at Day 22 for Regimen C)
PK Parameter: Clearance (CL) of Mirvetuximab Soravtansine and Total Antibody
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: CL of DM4 and SmDM4
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4
Blood samples from participants were analyzed to characterize PK when administered in 3- or 4-week cycles.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
PK Parameter: Time to Reach Cmax (Tmax) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were derived using non-compartmental PK analysis.
Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (up to 336 hours) (additionally at Day 22 for Regimen C)
Plasma Concentration of Bevacizumab
Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
Time frame: At end of infusion (EOI) of Cycle 1; and at pre-infusion and EOI of Cycles 2 to 6
Plasma Concentration of Carboplatin
Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
Time frame: At end of infusion, 6 and 24 hours post-infusion of Cycle 1; and at pre-infusion and end of infusion of Cycles 2, 4, 5 and 6; at pre-infusion, end of infusion and 6 and 24 hours post-infusion of Cycle 3
Plasma Concentration of Pegylated Liposomal Doxorubicin
Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
Time frame: At end of infusion of Cycle 1; and at pre-infusion and end of infusion of Cycles 2 to 6
Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine
Blood samples were collected to measure the presence of ADAs for mirvetuximab soravtansine. Seronegative is defined as a participant that tests negative at all visits. Treatment-emergent ADA is defined as a participant that is seronegative prior to dosing on Day 1 of Cycle 1 and tests positive in both screening and confirmatory assays at one or more subsequent visits. Treatment-unaffected ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of less than or equal to 4-fold (based on a 2-fold sample dilution). Treatment-boosted ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of more than a 4-fold increase (based on a 2-fold sample dilution).
Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 283.3 weeks)
| Milestone | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 11 | 0 | 0 | 0 | 4 | 4 | 10 | 4 | 5 | 7 | 4 | 10 | 0 | 0 |
| Received at least 1 dose of study drug | 3 | 11 | 0 | 0 | 0 | 4 | 4 | 10 | 4 | 5 | 7 | 4 | 10 | 0 | 0 |
| Completed | 3 | 11 | 0 | 0 | 0 | 4 | 4 | 10 | 4 | 5 | 7 | 4 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 21 | 34 | 60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 0 |
| Received at least 1 dose of study drug | 0 | 0 | 21 | 34 | 60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 21 | 34 | 60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 0 |
| Milestone | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Adverse events (AEs) were any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function that developed or worsened during the clinical study, not necessarily having a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes previously listed. TEAEs were any AE that emerged on or after the first dose, and within 30 days of the last dose. Serious and other non-serious AEs regardless of causality are reported in the AE module.
| Participants | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 3 | 126 | 4 | 4 | 10 | 4 | 4 | 7 | 4 | 56 | 41 |
| SAEs | 2 | 49 | 2 | 4 | 3 | 1 | 2 | 3 | 2 | 25 | 17 |
| Grade >=3 TEAEs | 2 | 85 | 2 | 4 | 7 | 2 | 3 | 6 | 1 | 30 | 37 |
ORR was defined as percentage of participants with confirmed response (complete response \[CR\] + partial response \[PR\]). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD. The 95% confidence interval (CI) was based on binomial distribution.
| percentage of participants | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|
| Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | 52 (29.78 to 74.29) | 29 (15.10 to 47.48) | 50 (36.81 to 63.19) | 27 (14.60 to 41.94) | 83 (67.94 to 92.85) |
ORR was defined as percentage of participants with confirmed response (CR + PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the SLD of target lesions, taking as reference the baseline SLD.
| percentage of participants | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response, as Assessed by RECIST Version 1.1 | 0 (0.00 to 0.00) | 45 (16.75 to 76.62) | 50 (6.76 to 93.24) | 50 (6.76 to 93.24) | 89 (51.75 to 99.72) | 0 (0.00 to 0.00) | 20 (0.51 to 71.64) | 29 (3.67 to 70.96) | 25 (0.63 to 80.59) | 50 (18.71 to 81.29) |
PFS was defined as the time from the date of the first dose of study drug until the date of PD or death from any cause, whichever occurred first, estimated using the Kaplan-Meier method. PFS was defined based on radiological assessments and determined by the investigator. PD was defined as at least a 20% increase in the SLD of target lesions, taking as reference the smallest (nadir) SLD since and including baseline. In addition to the relative increase of 20%, the SLD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
| months | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS); Time From the Date Of First Dose Until The Date Of Progressive Disease (PD) Or Death By Any Cause, As Defined By RECIST Version 1.1 | 13.49 (11.76 to NA) | 8.80 (1.18 to NA) | 9.92 (7.13 to NA) | 6.77 (4.63 to 10.71) | 8.28 (6.34 to 11.01) | 13.52 (10.38 to NA) | 32.94 (10.38 to NA) | 16.46 (6.97 to NA) | NA (1.68 to NA) | 7.03 (0.26 to NA) | 7.23 (1.45 to NA) | 2.53 (1.18 to NA) | 9.46 (1.38 to NA) | 4.17 (2.79 to 5.52) | 13.50 (9.86 to 16.30) |
DOR was defined as the time from the date of the first response (CR or PR), to the date of PD or death from any cause, whichever occurred first. DOR was only defined for patients who had a best overall response of CR or PR, estimated using the Kaplan-Meier method. The response-evaluable population included all patients with radiographic assessment at baseline, who received at least 1 dose of combination treatment and had at least 1 post-dose radiographic tumor assessment or who died within 105 days of first dose.
| months | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) Per RECIST v1.1 by Investigator Assessment | — | NA (2.76 to NA) | 11.96 (2.99 to NA) | 14.06 (3.91 to NA) | 10.38 (6.93 to 13.67) | NA (6.05 to NA) | 31.77 (9.20 to NA) | 12.12 (4.40 to NA) | — | NA (NA to NA) | NA (5.29 to NA) | 3.42 (NA to NA) | 8.31 (6.93 to NA) | 4.37 (2.79 to NA) | 10.87 (8.71 to 15.15) |
A CA-125 response was defined as a ≥ 50% reduction in CA-125 levels from baseline. GCIG CA125 response rate was defined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100. The CA-125 evaluable population included all participants whose pretreatment sample was ≥2.0 times the upper limit of normal, within 2 weeks prior to the first dose of combination treatment, and who had at least 1 post-baseline CA-125 evaluation.
| percentage of participants | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA)-125 Clinical Response Rate by Investigator Assessment | 100 (2.5 to 100.0) | 60 (26.2 to 87.8) | 75 (47.6 to 92.7) | 65 (44.3 to 82.8) | 71 (57.8 to 82.7) | 67 (9.4 to 99.2) | 100 (29.2 to 100.0) | 86 (42.1 to 99.6) | 0 (NA to NA) | 50 (1.3 to 98.7) | 50 (11.8 to 88.2) | 0 (NA to NA) | 63 (24.5 to 91.5) | 46 (29.5 to 63.1) | 100 (87.2 to 100.0) |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in micrograms/milliliter (µg/mL).
| µg/mL | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine: Cycle 1 | 135 ± 9.2 | 137 ± 14.5 | 159 ± 30.4 | 159 ± 17.2 | 150 ± 17.2 | 118 ± 15.4 | 108 ± 15.7 | 144 ± 19.3 | 115 ± 21.5 | 114 ± 15.8 | 146 ± 16.8 | 112 ± 4 | 156 ± 13.2 | 151 ± 17.4 | 144 ± 18.5 |
| Mirvetuximab Soravtansine: Cycle 3 | NA ± NA | 148 ± 15.8 | 164 ± 12.4 | 174 ± 14.1 | 137 ± 144 | 46 ± 999 | 121 ± 15.1 | 147 ± 12.1 | NA ± NA | 137 ± 15.4 | 142 ± 6.03 | 114 ± 20 | 165 ± 10.6 | 159 ± 15.7 | 128 ± 66.1 |
| Total Antibody: Cycle 1 | 121 ± 11.8 | 122 ± 12.9 | 152 ± 31.1 | 148 ± 24.2 | 153 ± 13 | 118 ± 18.2 | 102 ± 16.4 | 129 ± 11.8 | 111 ± 23.5 | 114 ± 18.6 | 152 ± 17.2 | 94.7 ± 34.2 | 124 ± 11.8 | 146 ± 16.4 | 144 ± 18.3 |
| Total Antibody: Cycle 3 | NA ± NA | 147 ± 25.1 | 177 ± 26.6 | 175 ± 22.7 | 180 ± 41 | 57.9 ± 238 | 122 ± 20.9 | 149 ± 15.5 | NA ± NA | 124 ± 3.32 | 140 ± 19 | 114 ± 17.8 | 160 ± 23 | 165 ± 17.4 | 146 ± 44.2 |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in nanograms (ng)/mL.
| ng/mL | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM4: Cycle 1 | 3.04 ± 21.8 | 4.71 ± 32.9 | 5.51 ± 35.8 | 6.32 ± 33.8 | 5.59 ± 37.5 | 2.96 ± 8.85 | 3.72 ± 28.7 | 6.4 ± 27.7 | 4.12 ± 47.5 | 3.93 ± 18.3 | 6.58 ± 86.4 | 4.54 ± 49.3 | 5.6 ± 31.2 | 5.27 ± 35.3 | 4.52 ± 38.4 |
| DM4: Cycle 3 | NA ± NA | 5.06 ± 30.5 | 4.57 ± 27.3 | 6.16 ± 43.8 | 5.45 ± 69.1 | 3.06 ± 23.4 | 3.38 ± 15 | 5.66 ± 31.2 | NA ± NA | 5.1 ± 34.4 | 7.02 ± 70.8 | 3.91 ± 5.81 | 4.91 ± 37.3 | 4.95 ± 33.3 | 4.44 ± 25.7 |
| S-methyl DM4: Cycle 1 | 3.61 ± 26.7 | 9.6 ± 65.5 | 11.5 ± 61.7 | 12.2 ± 68.9 | 12.2 ± 62.6 | 5.75 ± 56.3 | 7.91 ± 46.9 | 13 ± 37.5 | 7.23 ± 50.8 | 7.51 ± 58.1 | 11.9 ± 77.1 | 11.3 ± 56.6 | 17 ± 91.8 | 12.8 ± 63.6 | 8.64 ± 71.7 |
| S-methyl DM4: Cycle 3 | NA ± NA | 12.3 ± 71.1 | 11.8 ± 55.7 | 12.2 ± 51.9 | 12.5 ± 89.2 | 3.21 ± 220 | 6.79 ± 59.1 | 14.1 ± 43.9 | NA ± NA | 10.8 ± 55.7 | 17.6 ± 63 | 16.2 ± 11.1 | 18 ± 52.9 | 13 ± 71.6 | 9.49 ± 104 |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in mg\*hours (h)/mL.
| mg*h/mL | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine: Cycle 1 | 16.1 ± 2.34 | 17 ± 13.9 | 18.6 ± 22.2 | 18.4 ± 22.1 | 17.5 ± 19.8 | 14.8 ± 13.8 | 11.3 ± 23 | 16.3 ± 26.7 | 14 ± 23.8 | 15.2 ± 34.1 | 16.2 ± 33.1 | 12.1 ± 19.1 | 17 ± 30.5 | 16.9 ± 32.9 | 17.8 ± 26.3 |
| Mirvetuximab Soravtansine: Cycle 3 | NA ± NA | 21.6 ± 37.2 | 22.7 ± 14.1 | 22.8 ± 24.9 | 22.3 ± 16.7 | 15.2 ± 22.1 | 17.9 ± 16.1 | 19.9 ± 26.5 | NA ± NA | 17.4 ± 19.4 | 16.4 ± 14.1 | 14.4 ± 32.1 | 20.2 ± 28.2 | 20.9 ± 30.8 | 19.7 ± 20 |
| Total Antibody: Cycle 1 | NA ± NA | 20.6 ± 22.2 | 24.5 ± 31.4 | 23.5 ± 34.2 | 25.8 ± 22 | 18 ± 22.2 | 13.3 ± 29 | 21.6 ± 35.1 | 20.1 ± 55 | 17.8 ± 73.5 | 24.8 ± 26.2 | 16.8 ± 16.3 | 18.4 ± 49.1 | 20 ± 44.6 | 25 ± 25.4 |
| Total Antibody: Cycle 3 | NA ± NA | 24.2 ± 31.3 | 36.1 ± 23 | 34.7 ± 49.3 | 39.2 ± 20.1 | NA ± NA | — | 30 ± 26 | NA ± NA | NA ± NA | 29.1 ± 33.6 | NA ± NA | 20.1 ± 29.7 | 28.9 ± 55.2 | 35.8 ± 32.6 |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Note that '9999' is used because AUCinf cannot be calculated for n\<3.
| ng*h/mL | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM4: Cycle 1 | NA ± NA | 249 ± 12.6 | 253 ± 28.2 | 289 ± 30.9 | 272 ± 28.4 | 161 ± 15.2 | 202 ± 21.6 | 315 ± 55.6 | 223 ± 64.8 | 180 ± 19.7 | 262 ± 49.6 | 192 ± 33.2 | 269 ± 17.7 | 261 ± 31.6 | 256 ± 40.7 |
| DM4: Cycle 3 | NA ± NA | 282 ± 14.1 | 263 ± 31.4 | 315 ± 36.5 | 285 ± 27.2 | 146 ± 22 | 180 ± 17.4 | 295 ± 31.3 | NA ± NA | 200 ± 24.2 | 289 ± 53.6 | 163 ± 7.42 | 245 ± 29.7 | 260 ± 38.2 | 243 ± 29.2 |
| S-methyl DM4: Cycle 1 | NA ± NA | 1700 ± 51.5 | 1710 ± 73.2 | 1980 ± 60.7 | 2120 ± 62.1 | 1370 ± 49.2 | NA ± NA | 2160 ± 56.5 | 1510 ± 63.7 | 1660 ± 119 | 1830 ± 72.2 | 2050 ± 50 | 2930 ± 91.3 | 2460 ± 70.8 | 1830 ± 61.2 |
| S-methyl DM4: Cycle 3 | NA ± NA | 1730 ± 76.3 | 1620 ± 58.5 | 1930 ± 52.9 | 2120 ± 57.8 | 1130 ± 14.3 | 1600 ± 49.6 | 1600 ± 52.4 | NA ± NA | 1800 ± 80.8 | 2290 ± 70 | NA ± NA | 2280 ± 61.9 | 2080 ± 75.5 | 1550 ± 61.8 |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were calculated using standard non-compartmental methods. The terminal t½ is an estimate (extrapolation) of the time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half (50%). If extrapolated AUC was greater than 20% (due to insufficient number of participants with data samples) the upper range of t½ was not reported.
| h | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine: Cycle 1 | 104 (104 to 143) | 123 (89.5 to 146) | 124 (76 to 154) | 121 (59.1 to 161) | 126 (82.1 to 168) | 117 (97.8 to 119) | 123 (97.7 to 152) | 128 (92.5 to 151) | 124 (114 to 176) | 148 (67.6 to 187) | 137 (86.2 to 156) | 120 (115 to 135) | 126 (70.3 to 184) | 126 (57.5 to 173) | 122 (85.9 to 172) |
| Mirvetuximab Soravtansine: Cycle 3 | NA (NA to NA) | 132 (93.7 to 157) | 132 (100 to 178) | 128 (65.9 to 181) | 130 (84.9 to 199) | 124 (119 to 146) | 124 (116 to 161) | 137 (108 to 165) | NA (NA to NA) | 175 (76.6 to 237) | 119 (103 to 140) | 114 (97.8 to 118) | 132 (99.9 to 173) | 133 (62.5 to 192) | 140 (97.6 to 202) |
| Total Antibody: Cycle 1 | 142 (107 to 226) | 206 (114 to 330) | 182 (87.9 to NA) | 221 (76.2 to NA) | 200 (119 to 315) | 189 (156 to 225) | 170 (165 to 286) | 208 (109 to 333) | 231 (200 to 299) | 282 (80.6 to NA) | 249 (182 to 314) | 184 (168 to 209) | 182 (68.9 to 269) | 196 (58 to NA) | 215 (111 to NA) |
| Total Antibody: Cycle 3 | NA (NA to NA) | 235 (165 to NA) | 214 (127 to NA) | 228 (86.8 to NA) | 216 (146 to NA) | 214 (143 to NA) | 290 (160 to NA) | 214 (163 to NA) | NA (NA to NA) | 337 (94.5 to NA) | 230 (88.4 to NA) | 197 (135 to 278) | 269 (170 to NA) | 232 (70.3 to NA) | 251 (148 to NA) |
| DM4: Cycle 1 | 49.9 (40.5 to 121) | 74.4 (47.8 to 104) | 70.2 (47.2 to 99.7) | 61.9 (43.9 to 100) | 63.9 (40.1 to 124) | 59.4 (45 to 73.3) | 60.6 (40.4 to 124) | 52.4 (39.6 to 115) | 65.9 (48.6 to 120) | 55.8 (51.7 to 65.6) | 57.4 (43 to 91.4) | 46.4 (38 to 62.9) | 73.6 (42.8 to 131) | 59.4 (29.8 to 219) | 57.5 (39.9 to 116) |
| DM4: Cycle 3 | NA (NA to NA) | 83.8 (40.8 to 94.1) | 73.9 (32.8 to 102) | 71.1 (39.4 to 111) | 78.3 (19.1 to 109) | 68 (52.3 to 69.6) | 63.6 (59 to 111) | 74.1 (52.7 to 101) | NA (NA to NA) | 96 (71.7 to 105) | 64.4 (45.5 to 115) | 46.5 (41.7 to 65.5) | 64.6 (53.3 to 109) | 64 (33 to 161) | 63 (45.2 to 109) |
| S-methyl DM4: Cycle 1 | NA (NA to NA) | 132 (97 to 178) | 126 (97.8 to 245) | 129 (81.7 to 217) | 139 (94.1 to 209) | 128 (96 to 151) | NA (NA to NA) | 132 (99.2 to 165) | 168 (133 to 220) | 181 (156 to 285) | 154 (126 to NA) | 132 (106 to 169) | 134 (104 to 163) | 127 (73.4 to 253) | 126 (84.4 to 292) |
| S-methyl DM4: Cycle 3 | NA (NA to NA) | 128 (97.3 to 216) | 132 (94.8 to 172) | 126 (86.7 to 207) | 121 (79.1 to 196) | 140 (127 to 186) | 168 (107 to 233) | 124 (100 to 155) | NA (NA to NA) | 182 (165 to 251) | 169 (105 to 213) | 171 (130 to 192) | 148 (120 to 158) | 140 (88.3 to 253) | 138 (84.9 to 275) |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
| mL/h | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine: Cycle 1 | 19.2 ± 18.8 | 22 ± 17.2 | 22 ± 29.1 | 20.9 ± 23.3 | 23.4 ± 23.8 | 19.9 ± 10.1 | 28.9 ± 17 | 22 ± 26.1 | 21.2 ± 22.3 | 23.3 ± 38.6 | 24.5 ± 41.3 | 29.2 ± 17.1 | 23.9 ± 34.5 | 22.8 ± 34.5 | 22.1 ± 26.8 |
| Mirvetuximab Soravtansine: Cycle 3 | NA ± NA | 16.9 ± 34.4 | 17.7 ± 23 | 16.5 ± 26.9 | 18.3 ± 21.4 | 19.3 ± 17.9 | 18.2 ± 14 | 17.2 ± 24.9 | NA ± NA | 20.3 ± 23.9 | 24.3 ± 21.4 | 26.4 ± 25 | 18.3 ± 36.8 | 17.7 ± 35.6 | 19.2 ± 23.6 |
| Total Antibody: Cycle 1 | NA ± NA | 18 ± 23.8 | 17.5 ± 36.5 | 16.7 ± 33.9 | 16.3 ± 25.9 | 16.3 ± 19.8 | 24.5 ± 24.6 | 16.6 ± 36.1 | 14.7 ± 47.1 | 19.3 ± 83.4 | 15.7 ± 34.6 | 21.1 ± 15.2 | 22.6 ± 49.2 | 20 ± 44.7 | 16.1 ± 26.7 |
| Total Antibody: Cycle 3 | NA ± NA | 15 ± 34.3 | 11.7 ± 27.3 | 11.2 ± 43.3 | 10.7 ± 26 | NA ± NA | — | 11.1 ± 20.5 | NA ± NA | NA ± NA | 13.9 ± 40.5 | NA ± NA | 16.4 ± 63.9 | 12.9 ± 57.5 | 9.69 ± 38.1 |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
| L/h | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM4: Cycle 1 | NA ± NA | 29 ± 19.3 | 30.9 ± 31.5 | 25.2 ± 36.6 | 28.6 ± 33.3 | 35 ± 14.6 | 30.7 ± 26.8 | 21.8 ± 64.7 | 25.1 ± 59.3 | 37.4 ± 28.3 | 28.2 ± 52.2 | 35.5 ± 57.2 | 28.8 ± 30.7 | 27.7 ± 27.5 | 29.1 ± 40.4 |
| DM4: Cycle 3 | NA ± NA | 23.5 ± 26.4 | 28.9 ± 33 | 22.7 ± 39.7 | 27.2 ± 35.5 | 38.6 ± 16 | 34.5 ± 23.4 | 22.1 ± 45.8 | NA ± NA | 33.5 ± 41.5 | 26.6 ± 54.3 | 44.6 ± 22.3 | 28.8 ± 44.4 | 26.7 ± 31.8 | 29.5 ± 31.5 |
| S-methyl DM4: Cycle 1 | NA ± NA | 4.49 ± 40.2 | 4.77 ± 61.1 | 3.84 ± 57.9 | 3.82 ± 60.8 | 4.39 ± 52 | NA ± NA | 3.35 ± 70.6 | 3.9 ± 59.6 | 4.21 ± 119 | 4.17 ± 62.8 | 3.42 ± 73 | 2.78 ± 91.8 | 3.06 ± 63.2 | 4.25 ± 57.1 |
| S-methyl DM4: Cycle 3 | NA ± NA | 4.18 ± 66.4 | 4.97 ± 48.6 | 3.84 ± 50.5 | 3.87 ± 52.7 | 5.19 ± 20.3 | 4.19 ± 48.3 | 4.26 ± 59 | NA ± NA | 3.9 ± 83.4 | 3.45 ± 56.3 | NA ± NA | 3.22 ± 81.9 | 3.57 ± 63.9 | 4.78 ± 60.4 |
Blood samples from participants were analyzed to characterize PK when administered in 3- or 4-week cycles.
| L | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine Cycle 1 | 2.93 ± 18.2 | 3.63 ± 12.4 | 3.54 ± 19.7 | 3.31 ± 18.5 | 3.87 ± 25.2 | 3.23 ± 7.04 | 4.29 ± 11.9 | 3.52 ± 23.3 | 3.69 ± 17.9 | 3.8 ± 10.7 | 3.88 ± 24.1 | 4.58 ± 20.9 | 3.78 ± 21.8 | 3.59 ± 23.1 | 3.73 ± 23 |
| Mirvetuximab Soravtansine Cycle 3 | NA ± NA | 3.21 ± 14.1 | 3.25 ± 13.2 | 2.83 ± 23.3 | 3.23 ± 23.4 | 3.37 ± 13.3 | 3.4 ± 15.7 | 3.13 ± 12.5 | NA ± NA | 3.78 ± 16.6 | 3.98 ± 19 | 3.94 ± 15.4 | 3.28 ± 31 | 3.1 ± 25.8 | 3.51 ± 21.6 |
| Total Antibody Cycle 1 | NA ± NA | 4.38 ± 16.1 | 4.05 ± 22.7 | 3.9 ± 34.9 | 4.06 ± 23.9 | 4.03 ± 28.1 | 5.67 ± 10.7 | 4.27 ± 24.4 | 4.48 ± 39.2 | 5.01 ± 1.58 | 4.09 ± 17.2 | 5.33 ± 18.7 | 4.69 ± 23 | 4.09 ± 30.1 | 4.21 ± 25.6 |
| Total Antibody Cycle 3 | NA ± NA | 3.74 ± 23.7 | 3.17 ± 17.2 | 2.97 ± 34.6 | 2.95 ± 24.4 | NA ± NA | — | 3.09 ± 8.55 | NA ± NA | NA ± NA | 3.76 ± 49.6 | NA ± NA | 4.01 ± 57.5 | 3.28 ± 30.5 | 2.9 ± 25.4 |
| DM4 Cycle 1 | NA ± NA | 2590 ± 23.8 | 2490 ± 31.4 | 2010 ± 38.6 | 2240 ± 40.4 | 2670 ± 20.9 | 2580 ± 59.4 | 1720 ± 36 | 1880 ± 51.6 | 2730 ± 26.5 | 2010 ± 53.5 | 2100 ± 80.9 | 2410 ± 52.5 | 2060 ± 31.1 | 2350 ± 45.1 |
| DM4 Cycle 3 | NA ± NA | 2190 ± 20.7 | 2480 ± 24.3 | 1990 ± 43.7 | 2370 ± 35.9 | 3030 ± 7.84 | 3160 ± 7.05 | 1900 ± 55.6 | NA ± NA | 3300 ± 38.4 | 2140 ± 35.9 | 2930 ± 22.9 | 2450 ± 53.6 | 2270 ± 32.8 | 2450 ± 29.1 |
| SmDM4 Cycle 1 | NA ± NA | 911 ± 57.3 | 900 ± 67.1 | 731 ± 69.3 | 751 ± 66.7 | 932 ± 63.7 | NA ± NA | 652 ± 65 | 832 ± 61.6 | 1100 ± 114 | 855 ± 66.3 | 695 ± 81.2 | 547 ± 97.6 | 592 ± 66.4 | 840 ± 65.1 |
| SmDM4 Cycle 3 | NA ± NA | 761 ± 53.6 | 878 ± 48.6 | 698 ± 51.8 | 696 ± 51 | 1100 ± 1.87 | 833 ± 24.5 | 754 ± 60.7 | NA ± NA | 947 ± 82.5 | 773 ± 64.7 | NA ± NA | 621 ± 76.2 | 709 ± 59.1 | 891 ± 67.2 |
Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were derived using non-compartmental PK analysis.
| h | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine: Cycle 1 | 1.75 (1.52 to 1.85) | 1.9 (1.32 to 7.48) | 2.1 (1.63 to 7.8) | 1.92 (1.62 to 8.08) | 2.06 (1.42 to 24) | 1.68 (1.63 to 1.72) | 1.96 (1.72 to 7.78) | 1.86 (1.5 to 7.57) | 4.28 (1.22 to 7.62) | 1.73 (1.45 to 7.08) | 5.98 (1.73 to 8.05) | 2 (1.67 to 7.57) | 2.14 (1.87 to 7.72) | 2.12 (1.62 to 8.23) | 2.07 (1.47 to 8.22) |
| Mirvetuximab Soravtansine: Cycle 3 | NA (NA to NA) | 3.88 (0.967 to NA) | 3.46 (1.17 to 7.5) | 2.24 (1.02 to 7.37) | 1.49 (1.08 to NA) | 4.06 (0.95 to NA) | 1.02 (0.95 to 5.35) | 1.48 (1.07 to 5.97) | NA (NA to NA) | 4.04 (1.2 to 7) | 6.08 (1.15 to 7.33) | 1.45 (1.17 to 22) | 1.26 (1.15 to 7.1) | 1.5 (0.95 to 25.6) | 6.98 (0.95 to NA) |
| Total Antibody: Cycle 1 | 1.75 (1.52 to 5.52) | 1.9 (1.32 to 7.75) | 2.1 (1.63 to 25.6) | 1.9 (1.62 to 48.2) | 2.05 (1.48 to 9) | 1.68 (1.63 to 24.1) | 4.09 (1.72 to 7.78) | 1.88 (1.5 to 7.55) | 3.84 (1.63 to 6.75) | 1.87 (1.45 to 7.53) | 5.98 (1.67 to 25) | 4.82 (1.67 to 7.87) | 2.25 (1.88 to 48.9) | 2.08 (1.43 to 8.05) | 2.2 (1.13 to NA) |
| Total Antibody: Cycle 3 | NA (NA to NA) | 3.88 (0.967 to 48.9) | 3.68 (1.08 to 25.2) | 2.24 (1.02 to 27.2) | 1.49 (1.08 to NA) | 6.91 (1.02 to NA) | 1.03 (0.95 to 7.05) | 1.48 (1.17 to 5.83) | NA (NA to NA) | 1.23 (1.05 to 6.83) | 7.12 (6.08 to 49.6) | 7.1 (1.05 to 48.7) | 3.7 (1.15 to 24) | 1.63 (0.95 to 25.1) | 3.03 (0.967 to NA) |
| DM4: Cycle 1 | 7.2 (5.52 to 7.27) | 7.5 (1.32 to 26.4) | 7.78 (1.83 to 8.58) | 7.63 (0 to 22.4) | 7.58 (1.67 to 24) | 7.4 (1.72 to 7.6) | 7.56 (6 to 7.78) | 7.34 (5.87 to 21.5) | 7.12 (5.87 to 7.62) | 7.32 (6 to 7.53) | 5.98 (1.67 to 8.05) | 7.62 (7.53 to 7.87) | 7.7 (2.25 to 8.22) | 7.58 (1.73 to 24) | 7.67 (1.58 to 8.22) |
| DM4: Cycle 3 | NA (NA to NA) | 7 (1.25 to 7.75) | 7.06 (1.25 to 7.63) | 6.94 (1.08 to 7.82) | 6.96 (1.1 to NA) | 6.99 (6.82 to NA) | 6.96 (5.35 to 7.05) | 6.08 (5.03 to 7.77) | NA (NA to NA) | 6.89 (1.2 to 7) | 7.02 (6.08 to 7.33) | 7.1 (1.05 to 7.6) | 7.08 (1.33 to 7.45) | 7.03 (0.95 to 24.8) | 7.13 (0.95 to NA) |
| S-methyl DM4: Cycle 1 | 23.8 (7.2 to 119) | 23.9 (5.87 to 170) | 7.83 (5.87 to 46.7) | 7.83 (5.68 to 166) | 8.26 (6.05 to 170) | 48.2 (24.6 to 169) | 108 (25.4 to 170) | 7.34 (5.87 to 163) | 23.8 (6.75 to 23.9) | 23.8 (7.53 to 24.4) | 7.7 (5.98 to 50.4) | 7.72 (7.53 to 49.6) | 7.84 (6.17 to 167) | 8 (7.18 to 171) | 8.15 (6.93 to 167) |
| S-methyl DM4: Cycle 3 | NA (NA to NA) | 7.01 (5.83 to 24.6) | 7.17 (5.83 to 47.7) | 7.11 (5.67 to 48.7) | 7.41 (6.02 to NA) | 6.99 (6.82 to NA) | 15.1 (5.35 to 47.6) | 6.08 (5.03 to 21.3) | NA (NA to NA) | 7.04 (6.83 to 47.2) | 7.02 (6.08 to 7.33) | 7.1 (6.87 to 7.6) | 7.08 (6.08 to 7.45) | 7.12 (0.95 to 47.3) | 7.22 (0.95 to NA) |
Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
| ug/mL | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|
| Cycle 1 EOI | 368 ± 20.2 | 352 ± 31.9 | 406 ± 22.3 | 430 ± 19.3 | 448 ± 23.2 | 413 ± 23.9 |
| Cycle 2 Pre-infusion | 69.3 ± 37 | 66 ± 35.4 | 90.6 ± 57.8 | 87.5 ± 37.4 | 88.1 ± 35 | 92.5 ± 39.9 |
| Cycle 2 EOI | NA ± NA | 477 ± 23.8 | 429 ± 38.2 | 528 ± 20.8 | 559 ± 28.4 | 473 ± 44.6 |
| Cycle 3 Pre-infusion | NA ± NA | 79.9 ± 52.9 | 132 ± 17 | 117 ± 39.3 | 118 ± 51.2 | 127 ± 45.8 |
| Cycle 3 EOI | NA ± NA | 408 ± 59.2 | 540 ± 23.6 | 556 ± 17.8 | 616 ± 22.1 | 531 ± 33.1 |
| Cycle 4 Pre-infusion | NA ± NA | 133 ± 24.1 | 134 ± 51.1 | 141 ± 49.4 | 123 ± 78.2 | 132 ± 92.9 |
| Cycle 4 EOI | NA ± NA | 537 ± 25.2 | 539 ± 20.7 | 505 ± 39.1 | 584 ± 35.7 | 485 ± 128 |
| Cycle 5 Pre-infusion | NA ± NA | 134 ± 18.3 | 163 ± 28.9 | 151 ± 36.1 | 137 ± 61 | 153 ± 51 |
| Cycle 5 EOI | NA ± NA | 583 ± 31.1 | 565 ± 19.1 | 587 ± 20.3 | 558 ± 80.6 | 547 ± 24.1 |
| Cycle 6 Pre-infusion | NA ± NA | 80.7 ± 96.8 | 191 ± 27.6 | 149 ± 37.8 | 166 ± 29.6 | 170 ± 51.5 |
| Cycle 6 EOI | NA ± NA | 513 ± 29.1 | 574 ± 26.2 | 559 ± 23.9 | 654 ± 24.6 | 525 ± 39.8 |
Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
| ng/mL | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|
| Cycle 1: EOI | 10300 ± 11.3 | 1060 ± 35.2 | 13900 ± 19 | 11800 ± 25.6 |
| Cycle 1: 6 hours post-infusion | 2890 ± 45.6 | 3790 ± 10.3 | 3120 ± 151 | — |
| Cycle 1 24 hours post-infusion | 719 ± 4.77 | 913 ± 19.7 | 1030 ± 43.8 | 817 ± 35 |
| Cycle 2: Pre-infusion | 124 ± 14.8 | 142 ± 21.7 | 158 ± 13.5 | 170 ± 79.2 |
| Cycle 2: EOI | 10800 ± 22 | 11600 ± 18.5 | 11700 ± 80.9 | 11000 ± 146 |
| Cycle 3: Pre-infusion | NA ± NA | 245 ± 34.6 | 173 ± 35.9 | 203 ± 28.2 |
| Cycle 3: EOI | NA ± NA | 4170 ± 946 | 12100 ± 28.9 | 12300 ± 26.9 |
| Cycle 3: 6 hours post-infusion | 1140 ± 412 | 3890 ± 29.9 | 1630 ± 238 | — |
| Cycle 3: 24 hours post-infusion | NA ± NA | 1330 ± 27.3 | 1270 ± 41.3 | 1440 ± 49 |
| Cycle 4: Pre-infusion | 220 ± 31.8 | 243 ± 59.1 | 214 ± 20.6 | 250 ± 39.9 |
| Cycle 4: EOI | 8230 ± 43.9 | NA ± NA | 214 ± 20.6 | 12500 ± 29.9 |
| Cycle 5: Pre-infusion | 199 ± 41.8 | NA ± NA | 194 ± 37.9 | 270 ± 43 |
| Cycle 5: EOI | 10900 ± 36.9 | NA ± NA | 13800 ± 31.8 | 11200 ± 88.1 |
| Cycle 6: Pre-infusion | 251 ± 20.2 | NA ± NA | 234 ± 24.6 | 271 ± 45.4 |
| Cycle 6: EOI | 12100 ± 32.5 | NA ± NA | 12100 ± 32.1 | 10700 ± 77.9 |
Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.
| ng/mL | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 |
|---|---|---|---|
| Cycle 1: EOI | 18700 ± 8.72 | 24400 ± 14.3 | 26400 ± 7.85 |
| Cycle 2: Pre-infusion | — | NA ± NA | 226 ± 44.9 |
| Cycle 2: EOI | 17300 ± 17.1 | 25700 ± 6.88 | 26100 ± 12.1 |
| Cycle 3: Pre-infusion | NA ± NA | NA ± NA | 228 ± 63 |
| Cycle 3: EOI | NA ± NA | 26200 ± 12.8 | 26200 ± 14.3 |
| Cycle 4: Pre-infusion | — | NA ± NA | 151 ± 54.2 |
| Cycle 4: EOI | NA ± NA | 24300 ± 24.1 | 24400 ± 15.4 |
| Cycle 5: Pre-infusion | — | NA ± NA | 177 ± 81.1 |
| Cycle 5: EOI | NA ± NA | 23700 ± 17.1 | 25000 ± 11.3 |
| Cycle 6: Pre-infusion | — | NA ± NA | 157 ± 134 |
| Cycle 6: EOI | NA ± NA | 22900 ± 13.3 | 24600 ± 14.7 |
Blood samples were collected to measure the presence of ADAs for mirvetuximab soravtansine. Seronegative is defined as a participant that tests negative at all visits. Treatment-emergent ADA is defined as a participant that is seronegative prior to dosing on Day 1 of Cycle 1 and tests positive in both screening and confirmatory assays at one or more subsequent visits. Treatment-unaffected ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of less than or equal to 4-fold (based on a 2-fold sample dilution). Treatment-boosted ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of more than a 4-fold increase (based on a 2-fold sample dilution).
| Participants | Dose Escalation Phase | Dose Expansion Phase |
|---|---|---|
| Seronegative | 51 | 175 |
| Treatment-emergent ADA | 3 | 11 |
| Treatment-unaffected ADA | 7 | 11 |
| Treatment-boosted ADA | 1 | 5 |
Collected over From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 238.3 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | 5/126 (4%) | 49/126 (38.9%) | 125/126 (99.2%) |
| Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | 0/4 (0%) | 4/4 (100%) | 4/4 (100%) |
| Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | 0/10 (0%) | 3/10 (30%) | 10/10 (100%) |
| Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | 0/5 (0%) | 2/5 (40%) | 4/5 (80%) |
| Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 4/56 (7.1%) | 25/56 (44.6%) | 56/56 (100%) |
| Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | 2/41 (4.9%) | 17/41 (41.5%) | 41/41 (100%) |
| Event | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/3 | 3/126 | 0/4 | 3/4 | 0/10 | 0/4 | 0/5 | 1/7 | 0/4 | 4/56 | 1/41 |
| Small intestinal obstructionGastrointestinal disorders | 1/3 | 7/126 | 0/4 | 0/4 | 1/10 | 1/4 | 0/5 | 1/7 | 1/4 | 5/56 | 2/41 |
| VomitingGastrointestinal disorders | 1/3 | 0/126 | 0/4 | 0/4 | 0/10 | 0/4 | 0/5 | 1/7 | 0/4 | 3/56 | 1/41 |
| HeadacheNervous system disorders | 1/3 | 2/126 | 0/4 | 0/4 | 0/10 | 0/4 | 0/5 | 0/7 | 0/4 | 0/56 | 0/41 |
| HypertensionVascular disorders | 1/3 | 0/126 | 0/4 | 0/4 | 0/10 | 0/4 | 0/5 | 0/7 | 0/4 | 0/56 | 0/41 |
| Malignant gastrointestinal obstructionGastrointestinal disorders | 0/3 | 0/126 | 0/4 | 0/4 | 0/10 | 0/4 | 0/5 | 0/7 | 1/4 | 0/56 | 0/41 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/3 | 2/126 | 0/4 | 1/4 | 0/10 | 0/4 | 0/5 | 0/7 | 0/4 | 0/56 | 0/41 |
| Flank painMusculoskeletal and connective tissue disorders | 0/3 | 0/126 | 1/4 | 0/4 | 0/10 | 0/4 | 0/5 | 0/7 | 0/4 | 0/56 | 0/41 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/126 | 1/4 | 0/4 | 0/10 | 0/4 | 0/5 | 0/7 | 0/4 | 0/56 | 0/41 |
| Clostridium difficile colitisInfections and infestations | 0/3 | 0/126 | 0/4 | 0/4 | 0/10 | 0/4 | 1/5 | 0/7 | 0/4 | 0/56 | 0/41 |
| Event | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Mirvetuximab Soravtansine + Bevacizumab + Carboplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 85/126 | 4/4 | 3/4 | 5/10 | 3/4 | 4/5 | 4/7 | 2/4 | 32/56 | 34/41 |
| NauseaGastrointestinal disorders | 2/3 | 73/126 | 1/4 | 2/4 | 10/10 | 1/4 | 4/5 | 6/7 | 3/4 | 30/56 | 33/41 |
| FatigueGeneral disorders | 1/3 | 67/126 | 2/4 | 2/4 | 7/10 | 1/4 | 4/5 | 4/7 | 4/4 | 28/56 | 30/41 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/3 | 27/126 | 4/4 | 1/4 | 2/10 | 0/4 | 0/5 | 0/7 | 1/4 | 6/56 | 9/41 |
| ConstipationGastrointestinal disorders | 1/3 | 33/126 | 0/4 | 1/4 | 4/10 | 2/4 | 4/5 | 2/7 | 2/4 | 16/56 | 12/41 |
| Vision blurredEye disorders | 2/3 | 71/126 | 3/4 | 3/4 | 6/10 | 0/4 | 3/5 | 3/7 | 2/4 | 26/56 | 31/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 25/126 | 1/4 | 3/4 | 4/10 | 0/4 | 2/5 | 3/7 | 0/4 | 12/56 | 12/41 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 47/126 | 0/4 | 3/4 | 3/10 | 0/4 | 0/5 | 3/7 | 2/4 | 15/56 | 18/41 |
| HypokalaemiaMetabolism and nutrition disorders | 0/3 | 13/126 | 3/4 | 2/4 | 3/10 | 2/4 | 0/5 | 3/7 | 1/4 | 12/56 | 4/41 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 37/126 | 2/4 | 3/4 | 6/10 | 0/4 | 1/5 | 2/7 | 0/4 | 4/56 | 29/41 |
All participants who were enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.3 ± 11.85 | 65.5 ± 8.43 | 62.2 ± 7.40 | 61.4 ± 9.99 | 61.4 ± 9.87 | 59.3 ± 9.14 | 67.0 ± 7.07 | 66.0 ± 10.33 | 59.5 ± 12.07 | 65.2 ± 4.66 | 60.6 ± 5.35 | 58.3 ± 6.18 | 63.5 ± 10.81 | 61.1 ± 8.64 | 63.8 ± 9.40 | 62.3 ± 9.16 |
| Sex: Female, Male(Participants) | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 11 | 21 | 34 | 60 | 4 | 4 | 10 | 4 | 5 | 7 | 4 | 10 | 46 | 41 | 264 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 6 |
| Not Hispanic or Latino | 3 | 11 | 21 | 32 | 58 | 4 | 4 | 9 | 4 | 4 | 7 | 4 | 10 | 45 | 39 | 255 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| White | 3 | 10 | 21 | 32 | 53 | 4 | 4 | 10 | 4 | 5 | 7 | 4 | 10 | 43 | 39 | 249 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Mar 2021, 60 months.
Results were first posted in Feb 2024, 2 years 11 months after primary completion. A results delay was requested in Dec 2021.
Of 26 phase 1/2 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 74. This study's 60 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirvetuximab soravtansine
Carcinoma, Ovarian Epithelial →